The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) in the UK

Sep-14

Endocrinology Healthcare Cost Pharmacoepidemiology

AUTHORS : Cheryl Neslusan, Janssen Scientific Affairs LLC, Titusville, NJ, USA – Email: cneslusa@its.jnj.com

JOURNAL : Diabetologia

REFERENCE: 57(S1):S330

DOI : 10.1007/s00125-014-3355-0

Read more

More publications

Apr-25

Comparative effect of aspirin versus clopidogrel monotherapy on incident type 2 diabetes in patients with atherosclerotic cardiovascular diseases: A target trial emulation study

Diabetes Pharmacoepidemiology

Read more

Feb-25

Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement

Pharmacoepidemiology Rheumatology

Read more

Feb-25

Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension: cohort study

Pharmacoepidemiology Rheumatology

Read more